Current salvage therapies in Hodgkin lymphoma. Issue 6 (12th May 2022)

• Record Type: Journal Article
• Authors: Chohan, Karan; Ansell, Stephen M.
• Is Part Of: Leukemia & lymphoma. Volume 63:Issue 6(2022)
• Page Start: 1267
• Page End: 1280
• Publication Date: 2022-05-12
• Subjects: Salvage -- relapsed/refractory -- Hodgkin lymphoma; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2021.2024819
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Hodgkin lymphoma is a B-cell malignancy with approximately 85–95% complete remission rate following frontline therapy; however, relapsed/refractory disease occurs in roughly 10–30% of patients after treatment. Salvage therapy conventionally relies upon cytotoxic chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation. A considerable number of patients experience relapse after transplantation, and further salvage management has included the use of allogeneic transplantation and radiotherapy. In the past decade, novel therapies including, brentuximab vedotin, PD-1 inhibitors, and the incorporation of PET-imaging into management have changed the paradigm of relapsed/refractory disease care. Novel therapies have been investigated in both single and combination regimens with other novel therapies and traditional chemotherapies. There is promising early work into the utility of CD30.CAR-T cell therapy, AFM13, camidanlumab tesirine, novel PD-1 inhibitors, and JAK1/JAK2 inhibition in management. Herein, we will review current salvage therapies in Hodgkin lymphoma and future directions in relapsed/refractory disease management.